Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, December 18, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Epigenetic Variation as a Driver of Breast Cancer Risk
  Videos

Return

Epigenetic Variation as a Driver of Breast Cancer Risk
Imperial College London

Genetic epidemiology aims to use the natural variation in the genome to look for associations between particular genotypes and disease risk or prognosis. Epigenetic epidemiology, a new area of research, aims to address the same questions about disease risk and prognosis using the natural variation present in the epigenome. It is now apparent that the variation between individuals does not occur at the classical promoter CpG island, but in other areas of the gene and that these regions are yielding markers of both cancer risk and prognosis. We have identified a breast cancer risk marker in the ATM gene using blood samples collected from prospective cohorts. We have also analysed blood samples from an ovarian cancer clinical trial, SCOTROC1, to identify prognostic biomarkers of progression free survival, overall survival, response and toxicity. Lastly, we have also shown that cancer risk exposures, such as smoking, can affect the epigenome detectable in blood DNA and may provide a more accurate measure of long term exposures. These studies, therefore, support the hypothesis that epigenetic variation may be a driver of cancer risk or prognosis.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Novel Agent Decreases Neuropathic Pain in Patients with Type 2 Diabetes
Promising profile of disease modification and pain reduction leads to proof of concept trials.
Parkinson's Vaccine: EU-Team Launches Clinical Trial
Vaccine candidate based on proprietary technology by AFFiRiS AG.
Two Drugs are No More Effective Than One to Treat Common Kidney Disease
NIH study finds limited kidney benefit from more rigorous blood pressure treatment.
Gene Therapy Provides Safe, Long-Term Relief for Patients with Severe Hemophilia B
Gene therapy pioneered by St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital provides men with hemophilia B reliable relief from the bleeding disorder.
Themis Bioscience’s Vaccine Against Chikungunya Successful in Phase 1
Results presented at international conferences in Philadelphia and New Orleans.
Anti-Leukemia Drug May Also Work Against Ovarian Cancer
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn